标题
PI3K/AKT signaling pathway and cancer: an updated review
作者
关键词
-
出版物
ANNALS OF MEDICINE
Volume 46, Issue 6, Pages 372-383
出版商
Informa UK Limited
发表日期
2014-06-05
DOI
10.3109/07853890.2014.912836
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
- (2014) Julie E. Chang et al. Current Hematologic Malignancy Reports
- Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
- (2013) David Lebwohl et al. Annals of the New York Academy of Sciences
- Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion
- (2013) Yan Xie et al. BIOCHEMICAL PHARMACOLOGY
- Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
- (2013) Esther Castellano et al. CANCER CELL
- Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer
- (2013) Pradeep S. Tanwar et al. CARCINOGENESIS
- RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
- (2013) Ralph Fritsch et al. CELL
- Cell survival and metastasis regulation by Akt signaling in colorectal cancer
- (2013) Ekta Agarwal et al. CELLULAR SIGNALLING
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis
- (2013) Shuangjie Wu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
- (2013) Violeta Serra et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial
- (2013) Shuji Ogino et al. JNCI-Journal of the National Cancer Institute
- Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate
- (2013) York Posor et al. NATURE
- Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
- (2013) Hashem A. Dbouk et al. PLoS One
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoinositide 3-Kinase Gene Mutation Predisposes to Respiratory Infection and Airway Damage
- (2013) I. Angulo et al. SCIENCE
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- Regulation and cellular functions of class II phosphoinositide 3-kinases
- (2012) Marco Falasca et al. BIOCHEMICAL JOURNAL
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
- (2012) X. Liao et al. CLINICAL CANCER RESEARCH
- Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
- (2012) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
- (2012) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
- (2012) S. M. Brachmann et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function
- (2012) Kazuaki Yoshioka et al. NATURE MEDICINE
- KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
- (2012) Ignacio Garrido-Laguna et al. PLoS One
- A New Dimension to Ras Function: A Novel Role for Nucleotide-Free Ras in Class II Phosphatidylinositol 3-Kinase Beta (PI3KC2β) Regulation
- (2012) Katy A. Wong et al. PLoS One
- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
- (2011) C. Mao et al. ANNALS OF ONCOLOGY
- PIK3R1 (p85 ) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
- (2011) M. E. Urick et al. CANCER RESEARCH
- PTEN Level in Tumor Suppression: How Much Is Too Little?
- (2011) A. Carracedo et al. CANCER RESEARCH
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies
- (2011) J. W. Moroney et al. CLINICAL CANCER RESEARCH
- Second-line therapy for refractory renal-cell carcinoma
- (2011) Fable Zustovich et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
- (2011) B Weigelt et al. ONCOGENE
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors
- (2010) Julian Carretero et al. CANCER CELL
- MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)
- (2010) Ji-guang Zhang et al. CLINICA CHIMICA ACTA
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
- (2010) C. E. Edling et al. CLINICAL CANCER RESEARCH
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
- (2010) Stefano Barbi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PI3Kinase signaling in glioblastoma
- (2010) M. M. Lino et al. JOURNAL OF NEURO-ONCOLOGY
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
- (2010) Shivanni Kummar et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The genetic basis of kidney cancer: a metabolic disease
- (2010) W. Marston Linehan et al. Nature Reviews Urology
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer-derived mutations in the regulatory subunit p85 of phosphoinositide 3-kinase function through the catalytic subunit p110
- (2010) M. Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
- (2009) Margaret A. Knowles et al. CANCER AND METASTASIS REVIEWS
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
- (2009) Christina Gewinner et al. CANCER CELL
- Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
- (2009) Bijay S. Jaiswal et al. CANCER CELL
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- SHIP Regulates the Reciprocal Development of T Regulatory and Th17 Cells
- (2009) N. R. Locke et al. JOURNAL OF IMMUNOLOGY
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110 and are disrupted in oncogenic p85 mutants
- (2009) H. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
- (2009) Gary R. Hudes et al. SEMINARS IN ONCOLOGY
- The regulation and function of Class III PI3Ks: novel roles for Vps34
- (2008) Jonathan M. Backer BIOCHEMICAL JOURNAL
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- IGF-1 Mediates PTEN Suppression and Enhances Cell Invasion and Proliferation via Activation of the IGF-1/PI3K/Akt Signaling Pathway in Pancreatic Cancer Cells
- (2008) Jiachi Ma et al. JOURNAL OF SURGICAL RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Phosphoinositide 3-Kinase p110 Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
- (2008) E. Ciraolo et al. Science Signaling
- PIK3CAcancer mutations display gender and tissue specificity patterns
- (2007) Silvia Benvenuti et al. HUMAN MUTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now